Azish Sima, Garakyaraghi Mohammad, Vakhshoori Mehrbod, Heidarpour Maryam, Behjati Mohaddeseh, Kiyan Kiyan, Omoomi Sepehr, Fakhrolmobasheri Mohammad, Shafie Davood, Sarrafzadegan Nizal
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
ARYA Atheroscler. 2022 Jun;18(6):2515. doi: 10.48305/arya.2022.11840.2515. Epub 2022 Dec 1.
Garlic may have anti-oxidanmayti-hypertensive and anti-hyperlipidemic properties. However, the effects of its administration on cardiac function in heart failure (HF) patients impact require further investigation. We aimed to evaluate garlic prescription effects on cardiac outcomes and quality of life scores in Iranian HF patients.
From August to December 2020, a randomized, double-blind clinical trial was conducted. Individuals with heart failure (New York heart association (NYHA) functional class of II and III) referred to private clinics in Isfahan, Iran, were randomly assigned to intervention (n=80) and control (n=80) groups. They have received 500 mg of odorless garlic tablets or the same shape and dosage of placebo twice daily for three months. Laboratory data, cardiac outcomes (end-diastolic diameter, ventricular septal thickness, NYHA functional class, left ventricular ejection fraction), quality of life score (Minnesota living with HF questionnaire), and the Modified Borg Scale (MBS) were all evaluated at the baseline and the end of the trial.
The population's mean age was 58.1±13.5 years (55% males). Patients who consumed garlic had remarkably improved functional class compared to placebo takers and their baseline (NYHA practical class of II, 79.4% vs. 50.6%, P<0.001 and 79.4% vs. 54%, P=0.006, respectively). MBS levels were significantly lower among garlic consumers (baseline: 2.52±0.5, after three months: 2.2±1.06, P= 0.040).
Garlic administration may improve cardiac function and breathe in HF patients. Complementary research is necessary to confirm our findings.
大蒜可能具有抗氧化、抗高血压和抗高血脂特性。然而，其对心力衰竭（HF）患者心脏功能的影响尚需进一步研究。我们旨在评估大蒜制剂对伊朗HF患者心脏结局和生活质量评分的影响。
2020年8月至12月，进行了一项随机双盲临床试验。将转诊至伊朗伊斯法罕私人诊所的心力衰竭患者（纽约心脏协会（NYHA）功能分级为II级和III级）随机分为干预组（n = 80）和对照组（n = 80）。他们每天两次服用500毫克无味大蒜片或相同形状和剂量的安慰剂，持续三个月。在基线和试验结束时评估实验室数据、心脏结局（舒张末期直径、室间隔厚度、NYHA功能分级、左心室射血分数）、生活质量评分（明尼苏达心力衰竭生活问卷）和改良博格量表（MBS）。
人群平均年龄为58.1±13.5岁（55%为男性）。与服用安慰剂者及其基线相比，食用大蒜的患者功能分级有显著改善（NYHA实际分级为II级，分别为79.4%对50.6%，P<0.001和79.4%对54%，P = 0.006）。大蒜食用者的MBS水平显著较低（基线：2.52±0.5，三个月后：2.2±1.06，P = 0.040）。
服用大蒜可能改善HF患者的心脏功能和呼吸。需要进一步研究以证实我们的发现。
